| Literature DB >> 29859173 |
Jacques Galipeau1, Luc Sensébé2.
Abstract
Mesenchymal stromal cells (MSCs) have been the subject of clinical trials for more than a generation, and the outcomes of advanced clinical trials have fallen short of expectations raised by encouraging pre-clinical animal data in a wide array of disease models. In this Perspective, important biological and pharmacological disparities in pre-clinical research and human translational studies are highlighted, and analyses of clinical trial failures and recent successes provide a rational pathway to MSC regulatory approval and deployment for disorders with unmet medical needs.Entities:
Keywords: Crohn’s disease; FDA; biomarkers; clinical trials; efferocytosis; graft versus host disease; immune compatibility; mesenchymal stromal cells; thawing
Mesh:
Year: 2018 PMID: 29859173 PMCID: PMC6434696 DOI: 10.1016/j.stem.2018.05.004
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633